CLINICAL TRIALS AND OBSERVATIONS Maintenance therapy with thalidomide improves survival in patients with multiple myeloma
نویسندگان
چکیده
Michel Attal, Jean-Luc Harousseau, Serge Leyvraz, Chantal Doyen, Cyrille Hulin, Lofti Benboubker, Ibrahim Yakoub Agha, Jean-Henri Bourhis, Laurent Garderet, Brigitte Pegourie, Charles Dumontet, Marc Renaud, Laurent Voillat, Christian Berthou, Gerald Marit, Mathieu Monconduit, Denis Caillot, Bernard Grobois, Herve Avet-Loiseau, Philippe Moreau, and Thierry Facon, for the Inter-Groupe Francophone du Myélome (IFM)
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis
1Institute of Cancer Research, Royal Marsden Hospital, London, United Kingdom; 2Clinical Trials Research Unit, University of Leeds, Leeds, United Kingdom; 3St James’s University Hospital, Leeds, United Kingdom; 4Nottingham University Hospital, Nottingham, United Kingdom; 5Royal Devon and Exeter Hospital, Exeter, United Kingdom; 6Western General Hospital, Edinburgh, United Kingdom; 7University o...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS AND THERAPEUTIC TRIALS Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients
The role of maintenance therapy in multiple myeloma is controversial. Recent studies have shown an improvement in both progression-free and overall survival for patients receiving maintenance treatment with a combination of interferon and glucocorticoids, compared with interferon alone. The role of glucocorticoids alone as maintenance therapy has not been previously addressed. We compared alter...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Improved survival in multiple myeloma and the impact of novel therapies
Treatments for myeloma have expanded in the last decade, but it is not clear if the introduction of novel therapies and the increased use of high-dose therapy have translated into better outcome for patients with myeloma. We examined the outcome of 2 groups of patients seen at a single institution, one from time of diagnosis and the other from the time of relapse, to examine the survival trends...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Recent major improvement in long-term survival of younger patients with multiple myeloma
In the past, most patients with multiple myeloma (MM) died within 5 to 10 years after diagnosis. Within the past decade, several new therapeutic interventions have been introduced, including autologous stem-cell transplantation, thalidomide, lenalidomide, and bortezomib. We estimated trends in age-specific 5and 10-year relative survival of patients with MM in the United States from 1990-1992 to...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3
Gene expression profiling (GEP) of purified plasma cells 48 hours after thalidomide and dexamethasone test doses showed these agents’ mechanisms of action and provided prognostic information for untreated myeloma patients on Total Therapy 2 (TT2). Bortezomib was added in Total Therapy 3 (TT3), and 48 hours after bortezomib GEP analysis identified 80 highly survival-discriminatory genes in a tra...
متن کامل